7:10 PM
 | 
Jul 01, 2009
 |  BC Extra  |  Clinical News

SEP-225289 misses depression endpoint

Sepracor Inc. (NASDAQ:SEPR) said its SEP-225289 missed the primary endpoint of a significant reduction vs. placebo in depression symptoms in a Phase II trial in 514 patients....

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >